Want to see ETST full AI Analyst Report?
ETST Stock Chart & Stats
$0.12
-$0.01(-10.83%)
At close: 4:00 PM EDT
$0.12
-$0.01(-10.83%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.24
Previous CloseN/A
Volume149.15K
Average Volume (3M)44.92K
Market Cap
$25.88M
Enterprise Value$46.79
Total Cash (Recent Filing)$2.82M
Total Debt (Recent Filing)$353.16K
Price to Earnings (P/E)6.8
Beta2.48
Next Earnings
Nov 16, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding287,590,880
10 Day Avg. Volume74,750
30 Day Avg. Volume44,925
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)3.71
Price to Sales (P/S)0.73
P/FCF Ratio21.98
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.03
Revenue Forecast (FY)$42.99M
Bulls Say, Bears Say
Bulls Say
Strong ProfitabilityHealthy gross and net margins indicate the current business mix can generate meaningful earnings. If maintained, this profitability provides resources for reinvestment and helps cushion the company against moderate revenue volatility.
Debt-Free Balance SheetMinimal leverage limits interest and refinancing risk while preserving financial flexibility. A debt-free structure can support organic investment, acquisitions, and resilience if operating conditions weaken, although the improvement is relatively recent.
Expanded Pharmacy FootprintThe acquisition broadens geographic reach and strengthens the company’s compounding platform. Facility upgrades and planned sterile-compounding certification could create access to higher-margin services and support a more nationally scalable healthcare model.
Bears Say
Revenue ContractionA sharp top-line decline raises concerns about demand durability, customer retention, and the company’s ability to scale consistently. Sustained revenue weakness could eventually pressure margins, limit reinvestment, and reduce the benefit of the current profit base.
Cash Flow DurabilityPositive current cash generation is encouraging, but incomplete earnings conversion suggests working capital or other cash uses may constrain flexibility. Negative free cash flow in 2022–2023 also indicates that the present improvement may not yet be firmly established.
Acquisition Execution RiskThe strategic benefits depend on upgrading the facility and obtaining certification over a lengthy timeline. Delays, compliance costs, or operational integration issues could postpone higher-margin revenue, while the related-party structure adds governance sensitivity.
Earth Science Tech News
ETST FAQ
What was Earth Science Tech Inc’s price range in the past 12 months?
Earth Science Tech Inc lowest stock price was <$0.01 and its highest was $0.24 in the past 12 months.
What is Earth Science Tech Inc’s market cap?
Earth Science Tech Inc’s market cap is $25.88M.
When is Earth Science Tech Inc’s upcoming earnings report date?
Earth Science Tech Inc’s upcoming earnings report date is Nov 16, 2026 which is in 89 days.
How were Earth Science Tech Inc’s earnings last quarter?
Earth Science Tech Inc released its earnings results on Aug 07, 2026. The company reported $0.003 earnings per share for the quarter, beating the consensus estimate of $0 by $0.003.
Is Earth Science Tech Inc overvalued?
According to Wall Street analysts Earth Science Tech Inc’s price is currently Overvalued.
Does Earth Science Tech Inc pay dividends?
Earth Science Tech Inc does not currently pay dividends.
What is Earth Science Tech Inc’s EPS estimate?
Earth Science Tech Inc’s EPS estimate is 0.
How many shares outstanding does Earth Science Tech Inc have?
Earth Science Tech Inc has 287,590,880 shares outstanding.
What happened to Earth Science Tech Inc’s price movement after its last earnings report?
Earth Science Tech Inc reported an EPS of $0.003 in its last earnings report, beating expectations of $0. Following the earnings report the stock price went up 4.301%.
Which hedge fund is a major shareholder of Earth Science Tech Inc?
Currently, no hedge funds are holding shares in ETST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Earth Science Tech Inc
Earth Science Tech, Inc. (EST) is a biotechnology firm dedicated to the worldwide development and distribution of nutraceuticals, bioceuticals, and dietary supplements. These offerings aim to support general health, overall well-being, nutrition, and address specific needs within the cosmetic and alternative medicine sectors. The company's nutritional and dietary supplements are specifically formulated to help manage a wide range of conditions, including chronic and joint discomfort, inflammation, seizures, hypertension, cognitive decline, mood imbalances, weight management, nausea, and the physiological effects of aging, while also promoting overall vitality. EST's diverse product portfolio features items such as various hemp oils, essential vitamins and minerals, a broad selection of herbal and botanical extracts, personal care solutions, homeopathic remedies, and functional food products. These are offered in numerous forms, including capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herb preparations. Distribution channels include the company's own retail store, medical clinics, pharmacies, and online platforms. In addition to its wellness products, Earth Science Tech also provides medical equipment and devices. Founded in 2010, the company initially operated under the name Ultimate Novelty Sports, Inc. before officially rebranding to Earth Science Tech, Inc. in March 2014. Its corporate headquarters are located in Doral, Florida.
Technical Analysis
Ownership Overview
42.66% Insiders
―
Mutual Funds
― Other Institutional Investors
57.34% Public Companies and
Individual Investors